Straits Times Index
3,316.56 -6.06 (-0.18%) Nikkei
38,646.11 -457.11 (-1.17%) Hang Seng
18,608.94 -259.77 (-1.38%) FTSE 100
8,317.59 -21.64 (-0.26%) Bitcoin USD
69,101.45 +17.07 (+0.02%) CMC Crypto 200
1,482.17 +14.07 (+0.96%)
IOVA Jan 2025 2.500 put
| Previous close | 0.1400 |
| Open | 0.1000 |
| Bid | 0.1000 |
| Ask | 0.2500 |
| Strike | 2.50 |
| Expiry date | 2025-01-17 |
| Day's range | 0.1000 - 0.1400 |
| Contract range | N/A |
| Volume | |
| Open interest | 293 |
GlobeNewswireIovance Biotherapeutics to Present at Upcoming Conferences and Events
SAN CARLOS, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following conferences and events: TD Cowen 5th Annual Oncology Innovation Summit: Insights for ASCO & EHAFireside Chat: May 28, 2024 at 3:00 p.m. ETVirtual Iovance ASCO Invest
ZacksIovance (IOVA) Up 5% on Updated Data From Melanoma Study
Iovance (IOVA) shares updated data from a mid-stage study, which showed that treatment with its combination therapy achieved an objective response rate of 65% in frontline advanced melanoma.
- GlobeNewswire
Iovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual Meeting
Lifileucel TIL Cell Therapy in Combination with Pembrolizumab DemonstratesDeep, Durable Responses in Frontline Advanced Melanoma Patientsin IOV-COM-202 Clinical Study ASCO Oral Presentation to Highlight 65% Objective Response Rate (ORR) and 30% Complete Response Rate Nearly All Responses Remain Ongoing at a Median Follow-up of 21.7 Months in the Oral Presentation Data in Published Abstract and Upcoming Oral PresentationStrongly Support Ongoing TILVANCE-301 Phase 3 Trial SAN CARLOS, Calif., May 2
